NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines

by NImmune Biopharma | Sep 5, 2024 | Press Release

Download Press Release NImmune will leverage BioTherapeutics’ computational and preclinical services to accelerate biomarker-driven development of its LANCL immunoregulatory drug pipeline Growing scientific ecosystem also includes NIMML Institute’s TITAN-X...

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

by NImmune Biopharma | Nov 14, 2023 | Press Release

Download Press Release First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral treatment with NIM-1324 is well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 induces a dose-proportional change in...

NImmune Biopharma Announces Publication on the Safety, Efficacy and Novel LANCL2 Mechanism of Action of Omilancor in Inflammatory Bowel Diseases

by NImmune Biopharma | Nov 2, 2023 | Press Release

This publication describes novel LANCL2-based immunoregulatory mechanisms that enhance regulatory T cells (Tregs) anti-inflammatory functions by amplifying IL-2 signaling and promote T cell metabolic reprogramming resulting in enhanced mitochondrial metabolism...

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease

by NImmune Biopharma | Nov 2, 2023 | Research and White Papers

Lanthionine synthetase C-like 2 (LANCL2) therapeutics have gained increasing recognition as a novel treatment modality for a wide range of autoimmune diseases. Genetic ablation of LANCL2 in mice results in severe inflammatory phenotypes in inflammatory bowel disease...

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

by NImmune Biopharma | Oct 23, 2023 | Press Release

Download Press Release Once-a-day oral dosing with omilancor induced clinical remission in 30.4% of active Ulcerative Colitis (UC) patients versus 3.7% in the placebo group (Δ=26.7%, P = 0.01) Once-a-day oral dosing with omilancor in active Crohn’s disease (CD)...